{"title":"Correlation between plasma lncRNA <i>CASC11</i> and malignancy in lung adenocarcinoma patients and the prognostic value of lncRNA <i>CASC11</i>.","authors":"Xiaojuan Gu, Yanlin Zhang, Hao Xiong","doi":"10.2217/pme-2022-0104","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To study the connection between lncRNA <i>CASC11</i> plasma expression and clinical characteristics as well as prognoses of patients. <b>Methods:</b> Sixty lung adenocarcinoma (LUAD) patients and 60 healthy adults participated in this research. LncRNA <i>CASC11</i> expression was detected by quantitative real-time PCR and the relationships between lncRNA <i>CASC11</i> plasma expression and patient prognosis and clinical characteristics were analyzed. <b>Results:</b> LncRNA <i>CASC11</i> was highly expressed in LUAD tissues and plasma (p < 0.05). Receiver operating characteristic curve analysis indicated the diagnostic value of lncRNA <i>CASC11</i> in LUAD (p < 0.0001). Higher plasma lncRNA <i>CASC11</i> expression indicated worse patient prognoses (p < 0.05). Plasma lncRNA <i>CASC11</i> level was also closely related to tumor differentiation and tumor-node-metastasis stage (p < 0.05). <b>Conclusion:</b> Plasma lncRNA <i>CASC11</i> may be a potential biomarker for LUAD diagnosis and prognosis.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0104","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1
Abstract
Objective: To study the connection between lncRNA CASC11 plasma expression and clinical characteristics as well as prognoses of patients. Methods: Sixty lung adenocarcinoma (LUAD) patients and 60 healthy adults participated in this research. LncRNA CASC11 expression was detected by quantitative real-time PCR and the relationships between lncRNA CASC11 plasma expression and patient prognosis and clinical characteristics were analyzed. Results: LncRNA CASC11 was highly expressed in LUAD tissues and plasma (p < 0.05). Receiver operating characteristic curve analysis indicated the diagnostic value of lncRNA CASC11 in LUAD (p < 0.0001). Higher plasma lncRNA CASC11 expression indicated worse patient prognoses (p < 0.05). Plasma lncRNA CASC11 level was also closely related to tumor differentiation and tumor-node-metastasis stage (p < 0.05). Conclusion: Plasma lncRNA CASC11 may be a potential biomarker for LUAD diagnosis and prognosis.
期刊介绍：
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis.
The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
